Fast axonal transport (FAT) requires consistent energy over long distances to fuel the molecular motors that transport vesicles. We demonstrate that glycolysis provides ATP for the FAT of vesicles. Although inhibiting ATP production from mitochondria did not affect vesicles motility, pharmacological or genetic inhibition of the glycolytic enzyme GAPDH reduced transport in cultured neurons and in Drosophila larvae. GAPDH localizes on vesicles via a huntingtin-dependent mechanism and is transported on fast-moving vesicles within axons. Purified motile vesicles showed GAPDH enzymatic activity and produced ATP. Finally, we show that vesicular GAPDH is necessary and sufficient to provide onboard energy for fast vesicular transport. Although detaching GAPDH from vesicles reduced transport, targeting GAPDH to vesicles was sufficient to promote FAT in GAPDH deficient neurons. This specifically localized glycolytic machinery may supply constant energy, independent of mitochondria, for the processive movement of vesicles over long distances in axons.
INTRODUCTION
Fast axonal transport (FAT) is mediated by the molecular motors dynein and kinesin that transport cargos over long distances in neurons (Hirokawa et al., 2010 ). This extremely rapid and efficient transport is essential to deliver molecules such as trophic factors to nerve terminals that can be distant up to 1 m from cell bodies in the case of human motor neurons (Salinas et al., 2008) . FAT consumes energy because the dynein and kinesin motors require ATP to transport cargos along microtubules. Because kinesin hydrolyses one ATP per 8 nm step (Gennerich and Vale, 2009 ), nerve cells must have energy sources distributed throughout their axons for these molecular motors to function.
Glucose is the major source of brain energy and is required for normal brain function. Glucose breakdown occurs in the cytosol through the glycolytic pathway that converts glucose into pyruvate and generates free energy (Ames, 2000) . The net energetic balance of glycolysis is relatively low, with two ATP being produced from one molecule of glucose. In contrast to glycolysis, mitochondria produce 34 ATP molecules (Ames, 2000) and provide most of the energy used by the brain. However, mitochondria are not evenly distributed within neurons, and are most abundant at sites with a high-energy demand such as synapses and nodes of Ranvier (MacAskill and Kittler, 2010) .
One fundamental requirement for efficient FAT is a constant supply of ATP. How is ATP distributed within neurons to fuel the molecular motors? It also remains to be understood how ATP can be continuously provided to fast-moving vesicles in axonal segments devoid of mitochondria. These questions are of particular importance in the context of several neurodegenerative disorders, such as amyotrophic lateral sclerosis, Alzheimer's, Parkinson's, and Huntington's diseases, which are characterized by mitochondrial dysfunction and axonal transport defects (Hirokawa et al., 2010; Salinas et al., 2008) . Here we investigated the relative contributions of glycolysis and the mitochondrial respiratory chain in supplying ATP for FAT.
RESULTS

Mitochondria, GAPDH, and Axonal ATP
To reliably analyze vesicular FAT, we designed microfluidicbased devices derived from a previously described microfluidic culture platform (Taylor et al., 2005) . Embryonic rat cortical neurons can extend long processes into the channels, but only axons can reach the distal chamber located 450 mm away from the proximal chamber containing the cell bodies and most of the dendrites, as shown by Tau staining ( Figure S1A available online). We electroporated cortical neurons with fluorescent-tagged cargos and plated the neurons in microchambers. We performed FAT assays 3-5 days after the cells were plated, when axons had reached the distal chamber. We used brain-derived neurotrophic factor tagged with mCherry (BDNF-mCherry), which displays the characteristic features of a FAT-dependent cargo and retains BDNF function (Kwinter et al., 2009) . To selectively analyze axonal transport, we recorded vesicular dynamics in the distal part of the microchannels and generated kymographs from the video recordings. Analyzes of BDNF vesicle dynamics revealed fast and highly processive anterograde and retrograde movements ( Figure 1A ; Movie S1) at velocities similar to those previously reported (Kwinter et al., 2009) .
To analyze the distribution of mitochondria and of the key glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the microfluidic devices, we used a mitochondrial signal peptide fused to dsRed (Mito-DR) and GAPDH tagged with GFP (GADPH-GFP) and verified that the respective behaviors of these constructs in axons grown in microchannels were similar to that in cultured neurons. As previously reported (Miller Figure S1 .
and Sheetz, 2004; Tristan et al., 2011) , mitochondria were abundant in cell bodies and discontinuously distributed in neurites, whereas GAPDH was diffused throughout the cytoplasm ( Figure 1B ). The same pattern of distribution was observed in axons extending within the microchannels (Figure 1B) . Mitochondria exhibited characteristic dynamic behavior within the microchambers, and were either stationary, very dynamic, or changing directions (Movie S2) as illustrated by the two-color kymograph ( Figure 1B) . We also investigated the trafficking of BDNF-mCherry-containing vesicles and of mitochondria in the same axons and found no overlap between stationary or dynamic populations ( Figure S1B ). In contrast to mitochondria, GAPDH was diffuse throughout the cytosol of the chambered axons and its distribution did not appear to change over time ( Figure 1B) .
Although there are many reliable methods to measure ATP content within cells, the subcellular location of ATP is more difficult to resolve. To selectively determine changes in ATP content within axons, we took advantage of a genetically encoded fluorescent sensor that monitors ATP:ADP ratio in living cells (Berg et al., 2009 ). The ATP:ADP ratio was constant over long distances within the axons ( Figures 1C and 1D ). As the signal emitted by Perceval is pH-dependent, we measured possible variations in intracellular pH using the SNARF 5 probe and observed no major fluctuations throughout the axons. This suggests that there is a constant availability in ATP within axons that is provided by both mitochondria and glycolysis.
GAPDH but Not Mitochondria Is Critical for FAT We next determined whether mitochondrial H + -ATP-synthase inhibition by oligomycin, which blocks ATP production from the mitochondria (Chang and Reynolds, 2006) , or whether GAPDH inhibition by iodoacetate affected FAT in cultured cortical neurons. We first measured the efficacy of oligomycin and iodoacetate in modulating ATP content within neurons. We added 1 mM pyruvate to the iodoacetate-treated neurons to bypass glycolysis and to allow mitochondria to continue to produce ATP. A 5 min treatment with oligomycin (20 mM) induced a 25% reduction in ATP that reached to 80% after 30 min (Figure 2A) . In contrast, a 30 min iodoacetate treatment that leads to a strong inhibition of GAPDH ( Figure 2B ) reduced ATP by only 40%. We next measured ATP:ADP ratio using Perceval as in Figure 1A . We observed a dynamic response in the Perceval signal that correlated with the ATP content as measured within neuronal extracts. Oligomycin treatment produced a progressive and substantial reduction in the Perceval signal, whereas iodoacetate treatment was not as effective ( Figure 2C ). These results indicate that most of the ATP in neurons originated from the mitochondria and that mitochondria inhibition rather than GAPDH inhibition significantly reduced the ATP level in neurons. We next assessed BDNF vesicle dynamics in these conditions. After 30 min oligomycin treatment, when ATP is maximally reduced (Figure 2A ), mean anterograde and retrograde vesicle velocity was unaffected and the percentage of dynamic vesicles remained constant ( Figures 2D and S2A ). We next treated neurons with iodoacetate and pyruvate. In contrast to oligomycin-mediated inhibition of mitochondrial ATP, GAPDH inhibition reduced FAT of BDNF vesicles after as little as 5 min of iodoacetate treatment as shown in the kymograph and by the reduction in the velocities and dynamics of BDNF (Figures 2D and S2A ; Movie S1). In support for a specific effect of iodoacetate, we found a 50% inhibition of FAT when using its IC 50 concentration (Schmidt and Dringen, 2009) (Figure S2B ).
Although oligomycin had no effect on vesicle transport, it rapidly blocked mitochondria trafficking (Figures 2E and S2C ; Movie S2). On the other hand, iodoacetate had no effect on mitochondria dynamics even after 30 min of treatment. This indicates the lack of off-target effects of iodoacetate on molecular motors because the same motors are used for mitochondria and vesicles (Hirokawa et al., 2010) . These results are in agreement with previous studies indicating that loss of mitochondrial ATP production, but not the disruption of mitochondrial membrane potential or mitochondria morphology can induce the loss of mitochondria dynamics (Kaasik et al., 2007; Rintoul et al., 2003) . Together, these experiments suggest that GAPDH rather than mitochondria is critical for FAT.
We next took advantage of the identification of two mitochondria adaptor proteins, milton and Miro (Glater et al., 2006; Wang and Schwarz, 2009) , to specifically deplete mitochondria from axons and redistribute them into the cell bodies. Indeed, milton knockout flies show no mitochondria in their axons but have a normal axonal distribution of vesicles. This suggested that transport of vesicles may not strictly depend on mitochondria. Previous work showed that milton-C expression in neurons redistributes mitochondria into the cell bodies but does not alter mitochondria function (Glater et al., 2006) . We therefore expressed milton-C in cortical neurons and observed that mitochondria clustered within cell bodies so that axons were depleted of mitochondria ( Figure 3A) . By transfecting Perceval into neurons, we observed a progressive but marked reduction of ATP:ADP ratio within axons of neurons coexpressing milton-C whereas the ratio in the cell body remained high ( Figure 3B ).
We next coexpressed milton-C, GFP, and mito-DR in neurons and plated them in microchambers. Having verified that mitochondria were also absent from axons in microchannels as a result of milton-C expression ( Figure 3C ), we assessed BDNF vesicle dynamics in neurons expressing milton-C and BDNFmCherry. To make sure these axons are depleted from mitochondria, we added mitotracker to the medium and recorded vesicular transport in the distal part of the mitochondriadepleted axons. We found that the velocities of vesicles were largely unaffected ( Figure 3D ) compared to control neurons (Figure 1A) . Our results indicate that BDNF vesicles can move efficiently in axons both devoid of mitochondria and with reduced ATP:ADP ratio.
Silencing GAPDH Impairs FAT of BDNF, APP, and TrkB but Not Mitochondria Trafficking
We plated on coverslips cortical neurons silenced for GAPDH with a siRNA that specifically targets rat GAPDH mRNA. GAPDH knockdown substantially reduced GAPDH protein levels as shown by immunoblot analyzes ( Figure 4A ). We observed a significant reduction in both anterograde and retrograde transport of BDNF vesicles in GAPDH-silenced neurons (Figures 4B and 4C) . We also silenced GAPDH with another siRNA sequence in cortical neurons that were plated in microchambers (Figure S3A) . As with the first siRNA ( Figures 4A-4C ), we observed a significant decrease in transport (Figures S3B and S3C) . To verify the efficacy of the two siRNAs, we determined GAPDH activity and protein levels and observed a similar reduction (Figure S3D) . Finally, to control for any possible off-target effects, we restored GADPH protein levels in siRNA-treated neurons by coexpressing a mouse GAPDH-GFP construct that was insensitive to the rat GAPDH siRNA ( Figure 4A ). We observed a complete recovery of normal BDNF vesicle dynamics in axons (Figures 4B and 4C) .
Besides its role in glycolysis, GAPDH functions in other cellular processes such as DNA repair, membrane fusion, cytoskeletal dynamics, and cell death (Tristan et al., 2011) . To demonstrate that the inhibitory effect of silencing GAPDH on FAT is linked to its glycolytic activity, we coexpressed a siRNA-insensitive and catalytically inactive form of GADPH (GAPDH-GFP-C149G) (Figure 4A) . In contrast to GAPDH-GFP, the catalytically inactive construct was unable to restore the defective axonal transport induced by the siRNA (Figures 4B and 4C ). These results indicate that catalytically active GAPDH is required for FAT and that the mechanism involves sustained glycolytic activity.
We next analyzed the consequences of GAPDH silencing on the transport of other cargos. As for iodoacetate treatment we found no effect on mitochondria dynamics ( Figure 4D ) further indicating that mitochondria transport does not depend on GAPDH. We then investigated two other types of cargos: the amyloid-precursor protein APP fused to GFP (APP-GFP), a characteristic marker of FAT in neurons whose transport is kinesin-1-dependent (Kaether et al., 2000) and TrkB, the BDNF receptor fused to RFP (TrkB-RFP) that is trafficked bidirectionally within axons (Salinas et al., 2008) . Whereas, APP and TrkBcontaining vesicles motilities were not modified upon oligomycin treatment ( Figure S3E ), we observed a marked reduction in the transport of both cargos after GAPDH silencing (Figures 4E and 4F) suggesting that GAPDH could participate to the transport of many different types of vesicles.
In Vivo Silencing of GAPDH Reduces FAT in Drosophila Larvae Because glycolysis may have a preferentially predominant role in providing ATP in cultured neurons, we determined the consequences of GAPDH depletion on in vivo axonal transport in Drosophila melanogaster. We exploited the transparency of the larvae to record axonal transport (Pilling et al., 2006) . Larvae at L3 stage were placed between two coverslips and examined by videomicroscopy ( Figures 4G and 4H) . We used the UAS-GAL4 system to express synaptotagmin-GFP in the segmental nerves of Drosophila using the Ok6-Gal4 driver. We crossed these flies with UAS-shGAPDH flies to selectively deplete GAPDH in the motoneurons of the offspring. As control, we crossed the synaptotagmin-GFP flies to UAS-shZPG flies (see Extended Experimental Procedures). We observed a strong reduction in the velocity of synaptotagmin-GFP vesicles transport in flies expressing shGAPDH compared to that in flies expressing the shZPG ( Figure 4I ; Movie S3). The use of another UAS-shGAPDH Drosophila (shGAPDH(2)) line gave similar results ( Figure 4I ). We also found that the dynamics of mitochondria were not altered in flies that are silenced for GAPDH. (Figure 4J ). This further demonstrates in vivo our findings that transport of vesicles depends on GAPDH whereas transport of mitochondria does not.
Together, our results in cortical neurons and in Drosophila larvae demonstrate that (1) GAPDH is required for FAT in vitro and in vivo, (2) this mechanism might be general, and (3) this critical function has been evolutionarily conserved.
GAPDH Localizes on Vesicles
Although GAPDH is mainly cytosolic, it has also been reported to be in specific subcellular compartments including the cytoskeleton, membranes, and fusion vesicles (Tristan et al., 2011) .
iodoacetate-treated neurons (anterograde velocity, control: n = 275; oligomycin: n = 46; iodoacetate: n = 5; retrograde velocity, control: n = 235; oligomycin: n = 40; iodoacetate: n = 10; percentages of dynamic vesicles were calculated from respectively 13 (control), 7 (oligomycin) and 16 (iodoacetate) kymographs). (E) Neurons expressing Mito-DR plated in microchambers were treated with oligomycin or iodoacetate and pyruvate as in (A). Representative kymographs of Mito-DR, mean + SEM for anterograde and retrograde velocities and for the percentage of dynamic mitochondria in control, 5 min oligomycin-and 30 min iodoacetate-treated neurons (anterograde velocity, control: n = 44; oligomycin: n = 7; iodoacetate: n = 46; retrograde velocity, control: n = 51; oligomycin: n = 4; iodoacetate: n = 50; percentages of dynamic vesicles were calculated from respectively 7 (control), 10 (oligomycin) and 14 (iodoacetate) kymographs). *p < 0.5, ***p < 0.001. Error bars represent SEM. See also Figure S2 , and Movies S1 and S2. Therefore we analyzed whether GAPDH is located on brain vesicles. We performed subcellular fractionation of mouse brain and found GAPDH in the ''small vesicles'' fraction (P3) that also contained synaptophysin, BDNF and the p50 and p150 subunits of dynactin. We also detected dynein intermediate chain (DIC) and kinesin heavy chain (KHC) that are subunits of the corresponding molecular motors, dynein and kinesin-1 (Figures 5A  and S4 ). We next performed immunofluorescence experiments for endogenous GAPDH on neurons that were electroporated with BDNF-mCherry. We first permeabilized cells with saponin before fixation to remove the abundant cytosolic pool of GAPDH and selectively detect vesicle-associated GAPDH. We found a strong colocalization of endogenous GAPDH on BDNF-containing vesicles along axons as shown by confocal microscopy and reconstruction along the z axis. Quantification of the colocalization revealed a strong overlap between BDNF vesicles and GAPDH ( Figure 5B ) with 77.2% ± 7.6% of BDNF vesicles being positive for endogenous GAPDH (n = 102).
To further demonstrate that GAPDH is present on ''motile vesicles'' and has a functional role, we adapted a previously reported protocol (Perlson et al., 2009) the p50 dynamitin subunit of dynactin fused to GFP under the Thy1 neuronal promoter. These mice express p50-GFP at low concentration so that it does not disrupt the dynactin complex and thereby does not alter axonal transport . We first performed a subcellular fractionation of the brain tissue and obtained a cytoplasmic fraction containing small organelles, which we then subjected to sucrose gradient purification to enrich for vesicles (VF) ( Figures 5C and S4 ). This fraction contained GAPDH, endogenous p50, the transgenic p50-GFP, and the p150 dynactin subunit. This VF fraction also contained soluble proteins as shown by the presence of significant levels of tubulin. We next used an anti-GFP antibody to selectively immunopurify vesicles containing p50-GFP, which therefore represented neuronal motile vesicles (IP lane, Figures 5C and S4 ). This immunomagnetic purification of neuronal vesicles containing the motor complexes was effective as the IP fraction was greatly enriched in p50-GFP protein and eliminated soluble proteins as shown by the near to complete absence of tubulin in the IP fraction. In addition, no proteins were detected by BCA assay, Coomassie-stained gels or immunoblots from immunomagnetic purifications of nontransgenic mouse brains (data not shown). This indicates the lack of contamination by soluble proteins. The IP fraction contained BDNF, SNAP25, a vesicular protein, and components of the molecular motors complex such as DIC, endogenous p50, the p150 dynactin subunit, and low levels of kinesin. This is expected as a significant fraction of kinesin is in the cytosol and kinesin is recruited to vesicles upon activation ( Figure 5A ) (Colin et al., 2008) . This method therefore allowed us to highly purify vesicles that contain p50-GFP and the molecular motors complex, as well as proteins associated to these motile vesicles. Importantly, GAPDH was present in the IP fraction ( Figure 5C ). As phosphoglycerate kinase (PGK) is downstream of GAPDH and generates ATP during glycolysis, we tested whether PGK was also present with GAPDH on the vesicles. Like GAPDH, we also found PGK in the small vesicles fraction ( Figure 5A ) and in the immunopurified motile vesicles fraction ( Figure 5C ). Dynabeads coupled to anti-GFP antibodies were used to purify native intact vesicles from the vesicle fraction (VF) that were then labeled with a lipophilic marker ( Figures 5D and S4 ). These motile vesicles were immunopositive for GAPDH ( Figure 5D ) suggesting localization of GAPDH on the cytosolic face of the vesicles. To unequivocally demonstrate GAPDH localization, we performed immunocryoelectron tomography and found a significant number of gold particles on vesicles in presence of GAPDH antibodies compared to the situation without primary antibody ( Figure 5E , a and b; Movie S4). 3D reconstruction of tilt series and 3D volume rendering demonstrated the localization of GAPDH on the cytosolic face of the vesicles ( Figure 5E , c and d; Movie S4).
Motile Vesicles Show GAPDH Activity and Produce ATP We next investigated the role of vesicular GAPDH. First, purified motile vesicles were capable of substantial GAPDH activity (Figure 6A) . Next, we incubated the motile vesicles fraction (IP) with glyceraldehyde-3-phosphate, ADP, P i , and NAD+ to measure ATP production ( Figure 6B ). We observed a rapid and significant production of ATP under these conditions showing that both Blue pixels depict the vesicle, reddish pixels show iron bead used for vesicles purification and yellow pixels correspond to the IgGconjugated gold particle. Analysis of micrographies revealed an average number of gold particles associated to vesicles of 0.2 ± 0.2 for negative control and 1.1 ± 0.5 for immunolabeled sample (p < 0.05). See also Movie S4 and Figure S4 .
GAPDH and the downstream PGK are enzymatically active. ATP production required full GAPDH catalytic function, as it was completely blocked by iodoacetate. These results show that motile vesicles contain functional glycolytic machinery and produce ATP in an autonomous manner.
Vesicular GAPDH Is Transported within Axons
We next expressed GAPDH-GFP in cortical neurons and used videomicroscopy to analyze axons for the presence of GAPDH-GFP-labeled dynamic vesicles. As GAPDH is mainly cytosolic, we first bleached the axon within the microchannel to extinguish existing fluorescence. We observed fast-moving GAPDH-GFP-positive vesicles with high processive movements (Movie S5; Figure 6C ). To further demonstrate that GAPDH is present on fastmoving vesicles, we determined whether GAPDH-GFP and BDNF-mCherry were being cotransported on the same vesicles. As shown by the movie and kymograph analyzes (Movie S6; Figure 6D ), most of the dynamic vesicles containing BDNF-mCherry were also positive for GAPDH-GFP. We could also detect dynamic GAPDH-GFP-positive vesicles that were negative for BDNF-mCherry supporting a wider role of GAPDH in the transport of other vesicles such as synaptotagmin, APP, and TrkB-containing vesicles (Figure 4) . The findings that GAPDH is present on motile vesicles that are actively transported in axons suggest that vesicular GAPDH could provide energy support for axonal transport.
Vesicular GAPDH Is Sufficient to Promote FAT of Vesicles
To unequivocally address whether vesicular GAPDH is sufficient for FAT we silenced endogenous GAPDH and addressed GAPDH to vesicles through its fusion to the transmembrane domain of synaptotagmin ( Figure 6E ). The fusion protein called TM-GAPDH-GFP colocalized with BDNF-mCherry vesicles in axons ( Figure 6F) . Quantification of the colocalization revealed a strong overlap between BDNF vesicles and GAPDH with 72.2% ± 2.4% of BDNF vesicles found positive for TM-GAPDH (n = 326). TM-GAPDH-GFP was also detected in the vesicular fraction after subcellular fractionation ( Figure 6G ). However, in contrast to wild-type GAPDH and GAPDH-GFP, TM-GAPDH was not detected in the cytosol (S3 fraction, Figure 6G ). Reexpressing TM-GAPDH in neurons silenced for endogenous GAPDH was found sufficient to restore axonal transport. In contrast, a catalytically inactive vesicular GAPDH (C149G) was unable to restore axonal transport in these conditions ( Figure 6H ). These results indicate that a strictly vesicular GAPDH is sufficient to propel vesicles in axons.
Huntingtin Scaffolds GAPDH on Vesicles
To investigate the requirement of GAPDH on vesicles for FAT, we searched for the mechanism(s) that maintain GAPDH on vesicles with the goal of blocking GAPDH attachment to vesicles and analyzing axonal transport. Identifying such a mechanism would add further evidence for the specificity and the physiological relevance of GAPDH localization on vesicles.
GAPDH interacts with huntingtin (HTT), the protein that when mutated causes Huntington's disease (Bae et al., 2006; Burke et al., 1996; Culver et al., 2012; Goehler et al., 2004; Kaltenbach et al., 2007; Ratovitski et al., 2012) . HTT localizes on vesicles and is an essential scaffold protein regulating axonal transport of vesicles including BDNF (Caviston and Holzbaur, 2009; Colin et al., 2008; Gauthier et al., 2004) . We detected HTT in the motile vesicle fraction with GAPDH ( Figure 5C ). We immunostained neurons electroporated with BDNF-eGFP for endogenous HTT and GAPDH and selectively assessed the pool of vesicular associated proteins by saponin treatment. Both proteins colocalized within axons on BDNF vesicles ( Figure 7A ). To investigate whether HTT could scaffold GAPDH on vesicles, we silenced HTT using previously characterized siRNA that show no offtarget effects (Colin et al., 2008) . We observed a loss of GAPDH localization on BDNF vesicles ( Figure 7B ). We confirmed these findings in vivo by crossing Htt flox/flox mice (Dragatsis et al., 2000) with the inducible CamKII-CreER T2 line that express the CRE recombinase in the cortex and hippocampus upon tamoxifen treatment (see Extended Experimental Procedures) and performed subcellular fractionation from their cortices ( Figure 7C ). This successfully reduced HTT in all fractions. However, the GAPDH levels were only decreased in the vesicular fraction (P3) demonstrating that depletion of HTT reduces GAPDH attachment to vesicles. These results agree with the observation that HTT is a phenocopy of GAPDH because the silencing of either protein decreases the transport of BDNF, APP, and TrkB (Colin et al., 2008; Gauthier et al., 2004 ; G.L., unpublished data) ( Figure 4F ). Our findings also provide further evidence for the specific localization of GAPDH on vesicles.
Vesicular GAPDH Is Necessary to Promote FAT of Vesicles Our finding that HTT depletion leads to the detachment of GAPDH from vesicles but maintains GAPDH pool in the cytosol allowed us to address whether vesicular GAPDH is necessary to propel vesicles within axons. Therefore, we selectively decreased vesicular GAPDH by depleting HTT in cortical neurons and analyzed FAT ( Figures 7D and 7E ). We used two siRNA targeting different sequences of HTT and found that both RNAi decreased FAT when compared to scramble siRNA. The observed decrease in transport was similar to that of GAPDH-silenced neurons ( Figures 4C and 6H) . We re-expressed TM-GAPDH in HTT-silenced neurons and found that for both siHTT used, TM-GAPDH rescued axonal transport in both directions. Interestingly, forcing the vesicular localization of GAPDH on vesicles further increased the anterograde velocity of the vesicles compared to the control condition (GFP) or the C149G inactive point mutant ( Figure 7F ). This suggests that increasing the stoichiometry of GAPDH and consequently the local energy supply on vesicles further enhances the efficacy of transport. Together, we conclude that vesicular but not cytosolic GAPDH is required to propel vesicles at high velocities in axons.
DISCUSSION
We show that glycolytic enzymes located on vesicles rather than mitochondria are critical to maintain the high vesicular velocities that are characteristic of FAT. Perturbing glycolysis decreases FAT but does not totally block transport. Conversely, we found that FAT does not depend on the ATP generated by the mitochondria. However, our findings do not exclude the possibility that mitochondria could insure a basic transport within cells. GAPDH is a very abundant protein present both in the cytoplasm and the nucleus and is also reported to interact with microtubules and membranes (Tristan et al., 2011) . Could GAPDH present on MTs contribute to generate ATP for FAT of vesicles? The exact function of GAPDH on MTs is not fully understood, but GAPDH was shown to induce MT bundling (Huitorel and Pantaloni, 1985) . However, binding of the enzymatically active tetrameric form of GAPDH to MTs leads to its dissociation into a monomeric and inactive enzyme (Durrieu et al., 1987) suggesting a low glycolytic activity of GAPDH when bound to MTs. Another function for GAPDH on MTs could be linked to its vesicle fusion activity. Indeed, evidence suggests a role for GAPDH in the fusion of vesicles to membranes (Glaser and Gross, 1995; Tisdale, 2002) but this GAPDH-dependent membrane fusion is independent from its glycolytic activity (Tisdale et al., 2004) . Although we cannot exclude the possibility that MT-associated GAPDH could contribute to FAT, our findings that glycolytic enzymes are present on motile vesicles and produce ATP and, that a strictly vesicular GAPDH is necessary and sufficient to propel vesicles at high velocities in GAPDH-silenced neurons suggest that molecular motors could use preferentially this local pool of ATP generated by the vesicle itself.
Because GAPDH many studies that reported an interaction between HTT and GAPDH (Bae et al., 2006; Burke et al., 1996; Culver et al., 2012; Goehler et al., 2004; Kaltenbach et al., 2007; Ratovitski et al., 2012; Shirasaki et al., 2012) . We also found PGK on the motile fraction. Whether HTT also scaffolds other key enzymes of the glycolytic pathway such as PGK remains to be determined although this may be a possibility given the identification of such enzymes by proteomic or yeast two-hybrid approaches (Culver et al., 2012; Kaltenbach et al., 2007; Shirasaki et al., 2012) Also, it will be of interest to determine whether such scaffolding function is altered in Huntington's disease. Such studies may shed light on the mechanisms by which HTT regulates axonal transport in Huntington's disease and reconcile the defects in axonal transport and the observed defects in energetic homeostasis.
Although we show a crucial role for HTT in GAPDH attachment to vesicles, it is still possible that other mechanisms coexist. Indeed, the Rab2 GTPase that is required for protein transport within the early secretory pathway binds to and recruits GAPDH to vesicular membranes (Tisdale et al., 2004) . Similarly to the transport from the endoplasmic reticulum to Golgi, specific Rabs that remain to be identified could recruit GAPDH onto fast moving vesicles in axons. Another mechanism for the vesicular recruitment of GAPDH could involve posttranslational modifications of GAPDH, such as palmitoylation at cysteine 244 that was shown to increase recruitment of GAPDH to vesicles (Yang et al., 2005) .
The local vesicular ATP production by the glycolytic enzymes and its consumption by the molecular motors present on the same vesicles may provide rapid feedback between ATP production and changes in consumption, as has been shown in erythrocytes (Ames, 2000) . This concept of vesicular energetic coupling is also supported by a proteomic study that identified GAPDH and PGK on synaptic vesicles (Burré and Volknandt, 2007) and by the observation that glycolytic machinery activates the vesicular proton pump required for vesicle glutamate reuptake at the synapse (Ikemoto et al., 2003) . In addition, our results show that contrary to vesicular transport, mitochondrial traffic does not rely on glycolysis, but depends on mitochondrial ATP. Although similar to vesicular motors, the motors that transport mitochondria preferentially use ATP produced by the mitochondria rather than ATP generated by nonmitochondrial sources, such as the cytoplasmic glycolytic machinery. How the same motors-kinesin-1 is involved in the transport of both mitochondria and vesicles (Hirokawa et al., 2010) -discriminate between these different sources of ATP is likely to depend on the proximity of the energetic source and ensures the full efficacy of the cellular system.
In neurons, mitochondria are scattered in axons but enriched at subcellular locations that require high energy levels, such as synapses and nodes of Ranvier. Thus, along an axon, mitochondria can thereby be spared and may even be absent from large regions. Our findings that glycolytic machinery is present on fast-moving vesicles in axons indicate that neurons have constructed an autonomous transport system that is independent of the fluctuating energy levels that could occur in some regions of the axon.
EXPERIMENTAL PROCEDURES Mice
All experimental procedures were performed in strict accordance with the recommendations of the European Community (86/609/EEC) and the French National Committee (87/848) for care and use of laboratory animals.
Flies
Recombinant ok6-Gal4:UAS-Syt-GFP (X) flies and CCAP-G4/CyOA-G;UASmitoGFP/TM3SAG flies are gifts from M.-L. Parmentier and T. Schwarz, respectively. UAS-shGAPDH and UAS-shZPG strains were provided by Vienna Drosophila RNAi Center (VDRC). Generation of crosses and in vivo transport assay in fly larvae are detailed in Extended Experimental Procedures.
Microchambers and Neurons Plating
Microchambers were made according to Taylor et al. (2005) . For videomicroscopy or immunostaining, we first electroporated cortical neurons with fluorescent-tagged cargos and plated the neurons in microchambers. Microchambers fabrication and electroporation are detailed in Extended Experimental Procedures.
Videomicroscopy and Video Analyses
Live videomicroscopy of neuronal cultures or Drosophila larvae were carried out using an imaging system previously detailed (Gauthier et al., 2004) . Videomicroscopy and video analyses are detailed in Extended Experimental Procedures.
Immunoisolation of Vesicles and Immunocryoelectron Tomography
We selectively purified vesicles that contain p50-GFP from Thy:p50-GFP mouse brains through successive subcellular fractionation, sucrose gradient fractionation, and immunoisolation. Vesicles were either immunostained in native conditions and analyzed by confocal microscopy or processed for immunocryoelectron tomography (Extended Experimental Procedures).
Perceval Assay, GAPDH Activity, and ATP Production Neurons expressing Perceval were analyzed by Leica SP5 laser scanning confocal microscope. Perceval signal was quantified as the ratio of the ATP/ADP channels and controlled for pH variations (Extended Experimental Procedures). GAPDH activity was measured using the KDalert GAPDH Assay (Invitrogen). ATP production was measured using the CellTiter-Glo Luminescent Viability Assay (Promega) as detailed in Extended Experimental Procedures. Yang, J., Gibson, B., Snider, J., Jenkins, C.M., Han, X., and Gross, R.W. (2005) . Submicromolar concentrations of palmitoyl-CoA specifically thioesterify cysteine 244 in glyceraldehyde-3-phosphate dehydrogenase inhibiting enzyme activity: a novel mechanism potentially underlying fatty acid induced insulin resistance. Biochemistry 44, 11903-11912.
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